Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Rotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, Giménez-Arufe V, Balboa-Barreiro V, Margusino-Framiñán L, Mena-De-Cea Á, Vázquez-Rodríguez P, Castro-Iglesias Á, López-Calvo S, Martín-Herranz I, Míguez-Rey E, Cid-Silva P. Rotea-Salvo S, et al. Eur J Hosp Pharm. 2021 Oct 14:ejhpharm-2021-002896. doi: 10.1136/ejhpharm-2021-002896. Online ahead of print. Eur J Hosp Pharm. 2021. PMID: 34649965
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Margusino-Framiñán L, et al. Among authors: rotea salvo s. Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7. Eur J Hosp Pharm. 2020. PMID: 32296504 Free PMC article.
Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection.
Fernández-Oliveira C, Rotea-Salvo S, Fernández-Docampo M, González-Piñeiro S, Martín-Herranz I. Fernández-Oliveira C, et al. Among authors: rotea salvo s. Eur J Hosp Pharm. 2021 May 19:ejhpharm-2021-002805. doi: 10.1136/ejhpharm-2021-002805. Online ahead of print. Eur J Hosp Pharm. 2021. PMID: 34011555
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Míguez-Rey E, Cid-Silva P. Fernández-Bargiela N, et al. Among authors: rotea salvo s. Eur J Hosp Pharm. 2022 Jul;29(4):207-211. doi: 10.1136/ejhpharm-2020-002374. Epub 2020 Oct 13. Eur J Hosp Pharm. 2022. PMID: 33051194